HOUSTON, June 2, 2016 /PRNewswire-iReach/ -- Houston Health Ventures (HHV) has announced its investment in Luminostics, Inc. David Franklin, Managing Director of HHV states, "We are very excited to bring Luminostics' rapid biosensing platform into our portfolio. They are developing a very elegant at-home STD screening test as their first product."
Luminostics is a startup based on smartphone-based rapid test technology for diseases and other medical conditions developed at the University of Houston. Luminostics' vision is to empower consumers by enabling instant, on-demand access to health information at a molecular level. Luminostics' first product is a rapid at-home screening test for Chlamydia. It uses a smartphone's camera to interface with a nanotechnology-enabled disposal test cartridge and accurately read the test results. For more on the technology please see: https://youtu.be/7KnCpRAxiig
Bala Raja, CEO and co-founder of Luminostics reveals, "We're excited about leveraging our existing peer-reviewed funding with this private investment. We will be using it to further optimize our prototype and soon perform clinical testing in collaboration with Johns Hopkins University School of Medicine."
Andrew Paterson, CTO and co-founder of Luminostics adds, "The power of our platform lies in being easily adaptable to detect a wide variety of biological targets. We're looking forward to validating our technology through the Chlamydia screening test and expanding it further to other targets."
About Houston Health Ventures:
Houston Health Ventures (HHV) is an early stage venture capital company focused on medical devices, diagnostics, and health IT companies. HHV is located in Houston, Texas, the 4th largest city in the United States and home to the world's largest medical center. HHV provides a mechanism for individuals to get involved with early stage investing and provides entrepreneurs with additional mentorship and capital to continue on their path towards success. Interested parties can contact David@HoustonHealthVentures.com.
Luminostics is transforming smartphones into medical devices that can accurately detect and/or quantify biological targets including bacteria, viruses, hormones and protein biomarkers from tiny samples in less than 15 minutes. For more information please contact Bala Raja, email@example.com.
Media Contact: David Franklin, Houston Health Ventures, LLC, (281) 815-0689, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Houston Health Ventures